Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized …
M Khan, J Lin, G Liao, Y Tian, Y Liang, R Li, M Liu… - Medicine, 2018 - journals.lww.com
Background: Recently, immune checkpoint inhibitors have shown survival advantage over
chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). This meta-
analysis was conducted to gather and analyze the available evidence (Evidence level I;
Randomized Controlled Trials) comparing efficacy and safety of anti-programmed cell death-
1 (PD1)/programmed cell death ligand 1 (PD-L1) therapies and chemotherapy in the
treatment of advanced NSCLC. Methods: A search strategy was devised to identify the …
chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). This meta-
analysis was conducted to gather and analyze the available evidence (Evidence level I;
Randomized Controlled Trials) comparing efficacy and safety of anti-programmed cell death-
1 (PD1)/programmed cell death ligand 1 (PD-L1) therapies and chemotherapy in the
treatment of advanced NSCLC. Methods: A search strategy was devised to identify the …
以上显示的是最相近的搜索结果。 查看全部搜索结果